NORTHBROOK, Ill., May 16, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that new performance and clinical outcome data for three Verigene® multiplex infectious disease tests will be presented at the 114th General Meeting of the American Society for Microbiology (asm2014), to be held in Boston, Massachusetts on May 17 – 20, 2014.
Among the 12 posters being presented, seven will highlight performance of the recently FDA-cleared Verigene Gram-Negative Blood Culture Test (BC-GN) and the importance of rapid detection of multidrug-resistant gram-negative bacteria. Four posters will highlight clinical outcomes data for the FDA-cleared Verigene Gram-Positive Blood Culture Test (BC-GP). The remaining poster will compare the performance of the FDA-cleared Verigene Respiratory Virus Plus (RV+) Test with two other commercially available assays for detection of influenza and respiratory syncytial virus (RSV).
The following posters will be presented at asm2014 during the following dates and times in Exhibit Hall B:
Sunday, May 18th
- Poster 578: "Comparison of Three Multiplex Platforms for the Detection of Respiratory Tract Viruses," D. M. Coon, Fletcher Allen Health Care (Burlington, VT). [12:30 to 1:45 p.m.]
Monday, May 19th
- Poster 1141: "De-escalation of Antibiotics in Response to the Nanosphere Verigene Gram-Positive Blood Culture Assay," S. G. Beal, Baylor University Medical Center and med fusion Laboratory (Dallas and Lewisville, TX). [10:45 a.m. to 12:00 p.m.]
- Poster 1145: "Comparison of Verigene BC-GP to Peptide Nucleic Acid Fluorescence in situ Hybridization (PNA-FISH) in Conjunction with mecA Gene Detection for Staphylococcus aureus Bacteremia," B. K. Lopansri, Intermountain Healthcare (Salt Lake City, UT). [10:45 a.m. to 12:00 p.m.]
- Poster 1147: "Implementation and Accuracy of Rapid Molecular Diagnostics in Sepsis: Recipe for SUCCESS," M. S. Dekmezian, Baylor University Medical Center and med fusion Laboratory (Dallas and Lewisville, TX). [10:45 a.m. to 12:00 p.m.]
- Poster 1566: "Evaluation of the Nanosphere Verigene BC-GN for the Identification of Gram-Negative Bacilli and Detection of Antibiotic Resistance Mechanisms Directly from Positive Blood Cultures," J. T. Hill, Kaiser Permanente Northwest (Portland, OR). [12:30 to 1:45 p.m.]
- Poster 1567: "Evaluation of Verigene Gram-Negative Bacteria Blood Culture Nucleic Acid (BC-GN) RUO," P. Ferrieri, University of Minnesota (Minneapolis, MN). [12:30 to 1:45 p.m.]
- Poster 1568: "Performance of the Nanosphere Verigene BC-GN Assay in an Acute Care Inner-City Hospital," G. Hansen, Hennepin County Medical Center (Minneapolis, MN). [12:30 to 1:45 p.m.]
- Poster 1569: "Evaluation of the Verigene Gram-Negative Blood Culture Test (BC-GN) IUO," S. J. Diederich, NorthShore University HealthSystem (Evanston, IL). [12:30 to 1:45 p.m.]
- Poster 1570: "Evaluation of the Verigene BC-GN Assay for the Direct Identification of Gram-Negative Bacteria from Blood Culture," H. Berger, University of Washington (Seattle, WA). [12:30 to 1:45 p.m.]
- Poster 1571: "Verigene BC-GN Test for Rapid Detection of Gram-Negative Bacteria from Positive Blood Cultures in Pediatric Inpatients: A Multi-Center Evaluation," K. V. Sullivan, Children's Hospital of Philadelphia (PA) and Cincinnati Children's Hospital Medical Center (OH). [12:30 to 1:45 p.m.]
- Poster 1588: "Effects of Blood Volume on the Performance of the Verigene BC-GP Assay in Pediatric Patients," C. M. Polanco, Children's Hospital Los Angeles (CA). [12:30 to 1:45 p.m.]
Tuesday, May 20th
- Poster 2533: "Decreasing Turnaround Times in Septic Patients Infected with Carbapenemase Producing Gram-Negative Organisms, a First Look at an Emerging Technology," E. Steele, San Antonio Military Medical Center (Fort Sam Houston, TX). [12:30 to 1:45 p.m.]
Nanosphere representatives will be exhibiting at booth #427 in the asm2014 exhibit hall. In addition, the Company will be raising awareness of sepsis in support of Sepsis Alliance, a non-profit patient advocacy organization dedicated to educating about the disease so it can be prevented, detected and treated effectively.
About the Verigene® System
The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the blood, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.
About Nanosphere, Inc.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
CONTACT: Investors: Roger Moody, Chief Financial Officer 847-400-9021 firstname.lastname@example.org Michael Rice, LifeSci Advisors 646-597-6979 email@example.com Media: Lindsey Saxon, Director of Communications 847-400-9173 firstname.lastname@example.orgSource:Nanosphere, Inc.